<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1603233377
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOFRAN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        104.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sandoz Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.</p><p>&nbsp;</p><p>Zofran syrup is used for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preventing nausea and vomiting caused by chemotherapy (in adults and children) or radiotherapy for cancer (adults only)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preventing nausea and vomiting after surgery (adults only).</p><p>Ask your doctor, nurse or pharmacist if you would like any further explanation about these uses</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a) </strong><strong>Do not take Zofran syrup if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking apomorphine (used to treat Parkinson&rsquo;s disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to ondansetron or any of the other ingredients in Zofran syrup (listed in Section 6).</p><p>If you are not sure, talk to your doctor, nurse or pharmacist before taking Zofran syrup.</p><p>&nbsp;</p><p><strong>b) </strong><strong>Take special care with Zofran syrup</strong></p><p>Check with your doctor, nurse or pharmacist before taking Zofran syrup if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had heart problems (e.g. congestive heart failure which causes shortness of breath and swollen ankles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an uneven heart beat (arrhythmias)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to medicines similar to ondansetron, such as granisetron or palonosetron</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a blockage in your gut</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have problems with the levels of salts in your blood, such as potassium, sodium and magnesium.</p><p>If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before taking Zofran syrup.</p><p>&nbsp;</p><p><strong>c)&nbsp; </strong><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Please tell your doctor, nurse or pharmacist if you are taking or have recently taken or might take other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Zofran can affect the way some medicines work. Also some other medicines can affect the way Zofran works.</p><p>&nbsp;</p><p>In particular, tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine or phenytoin used to treat epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin<strong> </strong>used to treat infections such as tuberculosis (TB)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics such as erythromycin or ketoconazole</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-arrhythmic medicines used to treat an uneven heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_223" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:-148.95pt;margin-top:16.5pt;width:54pt;height:1in;text-indent:0;
 z-index:251656704;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>PONV wording</p></td></tr></tbody></table></td></tr></tbody></table><p>beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tramadol, a pain killer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect the heart (such as haloperidol or methadone)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer medicines (especially anthracyclines and trastuzumab)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine.</p><p>If you are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before having Zofran syrup.</p><p><strong>Tell your doctor or pharmacist immediately if you get any of these symptoms during and after the treatment with Zofran</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience sudden chest pain or chest tightness (myocardial ischemia).</p><p>&nbsp;</p><p><strong>d) </strong><strong>Pregnancy and breast-feeding</strong></p><p>Only use during the first trimester of pregnancy after discussion with your doctor of the potential benefits and risks to you and your unborn baby of the different treatment options. This is because Zofran can slightly increase the risk of a baby being born with cleft lip and/or cleft palate (openings or splits in the upper lip and/or the roof of the mouth). If you are already pregnant, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Zofran. If you are a woman of childbearing potential you may be advised to use effective contraception.</p><p>&nbsp;</p><p>Do not breast-feed if you are taking Zofran. This is because small amounts pass into the mother&rsquo;s milk. Ask your doctor or midwife for advice.</p><p>&nbsp;</p><p>e)&nbsp; <strong>Important information about some of the ingredients of Zofran syrup</strong><br />This medicine contains sorbitol (E420). Calorific value 2.6&nbsp;kcal/g sorbitol. If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor before taking this medicine. Sorbitol may have a mild laxative effect.</p><p>&nbsp;</p><p>This medicinal product contains small amounts of ethanol (alcohol), less than 0.004&nbsp;ml in a 5&nbsp;ml spoonful.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Zofran syrup exactly as your doctor has told you. You should check with your doctor, nurse or pharmacist if you are not sure. The dose you have been prescribed will depend on the treatment you are having.</p><p>&nbsp;</p><p>Do not mix Zofran syrup with anything (not even water) before swallowing it.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To prevent nausea and vomiting from chemotherapy or radiotherapy </strong></p><p>On the day of chemotherapy or radiotherapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the usual adult dose is 8&nbsp;mg taken one to two hours before treatment and another 8&nbsp;mg twelve hours after<strong>.</strong></p><p>On the following days</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the usual adult dose is two 5&nbsp;ml spoonfuls twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_225" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:-157.95pt;margin-top:4.5pt;width:54pt;height:1in;text-indent:0;
 z-index:251658752;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>CINV wording</p></td></tr></tbody></table></td></tr></tbody></table><p>this may be given for up to 5&nbsp;days.</p><p>&nbsp;</p><p>&nbsp;</p><p>Children aged over 6&nbsp;months and adolescents:</p><p>The doctor will decide the dose depending on the child&rsquo;s size (body surface area) or weight. Look at the label for more information.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the usual dose for a child is up to one 5&nbsp;ml spoonful twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; this can be given for up to 5&nbsp;days.</p><p>&nbsp;</p><p><strong>To prevent nausea and vomiting after an operation</strong></p><p>The usual adult dose is four 5&nbsp;ml spoonfuls before your operation.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_224" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='position:absolute;margin-left:-148.95pt;margin-top:1.5pt;width:54pt;
 height:1in;z-index:251657728;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEADOjPrwYDAADSBwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzkVU1PGzEQvVfqf7B8ag+QTUhCiNgg
SAmqRCFKoD1PvN6sVa+9tZ0vfn3H9hK2tKVSP05dhDLeGT/PvHk7Pj3blpKsubFCq5S2DxNKuGI6
E2qZ0vu7ycGAEutAZSC14indcUvPRq9fncJwaaAqBCOIoOwQUlo4Vw1bLcsKXoI91BVX6Mu1KcHh
0ixbmYENIpey1UmSfqsEoejoCeodOCArI34DSmr2mWdjUGuwCCnZsPmmzlGyP0eGoVpfmWpeTY3P
nN2sp4aILKXInIISKaKt2lGH4bL1bNfyCWCbm9LH6zwn25QenBwfd/o9SnYp7XUH7aNOEvH41hGG
Af1Bb5DgWQwDTtrdLtrxvOL2FwisuHwRA5OMyaDRSNBWPj21/r7i9mPFdz65C70lnU53X72PJ26L
r1FXocu2usYuWaL0uAC15OfG6E3BIbM+ItKEfMaDAmWPZ1qPtdh80BnyCyunA97foW5fNgwrY90V
1yXxRkoNZy4cBOtr62J+jyGeE6ulyCZCyrAwy8VYGrIGmdJJeOqSvgmTimywcb1OL1LyU4gkPD+C
KIXjhkhRphSVgE+k3BN5qbIgBgdCRhurkyoI0HPoE3Xbeeiob022828W+Iv8Go01o7JwGqBRaPNA
yQa/8ZTaLyswnBL5XmGrguoocWHR7R2jQolpehZNDyiGUCl1lERz7HCFW1aVEcsCT4riUPoc+5qL
mueYk89OWjd3O8lDYSFzL4YSzHWAQWPmjdCDil3wvLamzsZmBH6QB9v0nufuhbjgxS01ZYE3g6dK
lG1KuTq4usCx+IC5e/o9EM9zVEuUCeYMTijidhXPgaFkx1fkTpTckjef2m9juzg0/NF5wzdkpktQ
lFSgtMWNSQf/+slR0ku6+N9Bq4te4VgxgVJIHAJtnNCsAGN5aF+gidl/Bo6sIBO+ZDea3t58JBtt
/G3hZxxS6t2BD5VNwcCsSdr9/D8mje8JCSShkD1h+29wZfm8mqGE4piJHylG+Onbenabha317euv
zOZ69BUAAP//AwBQSwMEFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAABjbGlwYm9hcmQvdGhlbWUv
dGhlbWUxLnhtbOxZzW/cRBS/I/E/jHxvs9/NRt1U2c1uA23aKNkW9Thrz9rTjD3WzGzSvaH2iISE
KIgDlbhxQEClVuJS/ppAERSp/wJvZmyvJ+uQtI2gguaQtZ9/877fm6/LV+7FDB0QISlPel79Ys1D
JPF5QJOw590ajy6sekgqnASY8YT0vDmR3pX199+7jNd8RtMJxyIYRyQmCBglcg33vEipdG1lRfpA
xvIiT0kC36ZcxFjBqwhXAoEPQUDMVhq1WmclxjTx1oGj0oyGDP4lSmqCz8SeZkNQgmOQfnM6pT4x
2GC/rhFyLgdMoAPMeh7wDPjhmNxTHmJYKvjQ82rmz1tZv7yC17JBTJ0wtjRuZP6ycdmAYL9hZIpw
Ugitj1rdS5sFfwNgahk3HA4Hw3rBzwCw74OlVpcyz9Zotd7PeZZA9nGZ96DWrrVcfIl/c0nnbr/f
b3czXSxTA7KPrSX8aq3T2mg4eAOy+PYSvtXfGAw6Dt6ALL6zhB9d6nZaLt6AIkaT/SW0DuholHEv
IFPOtirhqwBfrWXwBQqyocguLWLKE3VSrsX4LhcjAGggw4omSM1TMsU+5OQAxxNBsRaA1wgufbEk
Xy6RtCwkfUFT1fM+THHilSAvn33/8tkTdHT/6dH9n44ePDi6/6Nl5IzawklYHvXi28/+fPQx+uPJ
Ny8eflGNl2X8rz988svPn1cDoXwW5j3/8vFvTx8//+rT3797WAHfEHhSho9pTCS6QQ7RLo/BMOMV
V3MyEa82YhxhWh6xkYQSJ1hLqeA/VJGDvjHHLIuOo0efuB68LaB9VAGvzu46Cu9FYqZoheRrUewA
tzlnfS4qvXBNyyq5eTxLwmrhYlbG7WJ8UCV7gBMnvsNZCn0zT0vH8EFEHDV3GE4UDklCFNLf+D4h
FdbdodTx6zb1BZd8qtAdivqYVrpkTCdONi0GbdEY4jKvshni7fhm+zbqc1Zl9SY5cJFQFZhVKD8m
zHHjVTxTOK5iOcYxKzv8OlZRlZJ7c+GXcUOpINIhYRwNAyJl1ZibAuwtBf0aho5VGfZtNo9dpFB0
v4rndcx5GbnJ9wcRjtMq7B5NojL2A7kPKYrRDldV8G3uVoh+hzjg5MRw36bECffp3eAWDR2VFgmi
v8yEjiW0aqcDxzT5u3bMKPRjmwPn146hAT7/+lFFZr2tjXgD5qSqStg61n5Pwh1vugMuAvr299xN
PEt2CKT58sTzruW+a7nef77lnlTPZ220i94KbVevG+yi2CyR4xNXyFPK2J6aM3JdmkWyhHkiGAFR
jzM7QVLsmNIIHrO+7uBCgc0YJLj6iKpoL8IpLLDrnmYSyox1KFHKJWzsDLmSt8bDIl3ZbWFbbxhs
P5BYbfPAkpuanO8LCjZmtgnN5jMX1NQMziqseSljCma/jrC6VurM0upGNdPqHGmFyRDDZdOAWHgT
FiAIli3g5Q7sxbVo2JhgRgLtdzv35mExUTjPEMkIBySLkbZ7OUZ1E6Q8V8xJAORORYz0Ju8Ur5Wk
dTXbN5B2liCVxbVOEJdH702ilGfwIkq6bo+VI0vKxckSdNjzuu1G20M+TnveFPa08BinEHWp13yY
hXAa5Cth0/7UYjZVvohmNzfMLYI6HFNYvy8Z7PSBVEi1iWVkU8N8ylKAJVqS1b/RBreelwE2019D
i+YqJMO/pgX40Q0tmU6Jr8rBLlG07+xr1kr5TBGxFwWHaMJmYhdD+HWqgj0BlXA0YTqCfoFzNO1t
88ltzlnRlU+vDM7SMUsjnLVbXaJ5JVu4qeNCB/NWUg9sq9TdGPfqppiSPydTymn8PzNFzydwUtAM
dAR8OJQVGOl67XlcqIhDF0oj6o8ELBxM74BsgbNY+AxJBSfI5leQA/1ra87yMGUNGz61S0MkKMxH
KhKE7EBbMtl3CrN6NndZlixjZDKqpK5MrdoTckDYWPfAjp7bPRRBqptukrUBgzuef+57VkGTUC9y
yvXm9JBi7rU18E+vfGwxg1FuHzYLmtz/hYoVs6odb4bnc2/ZEP1hscxq5VUBwkpTQTcr+9dU4RWn
WtuxlixutHPlIIrLFgOxWBClcN6D9D+Y/6jwmb1t0BPqmO9Cb0Vw0aCZQdpAVl+wCw+kG6QlTmDh
ZIk2mTQr69ps6aS9lk/W57zSLeQec7bW7CzxfkVnF4szV5xTi+fp7MzDjq8t7URXQ2SPlyiQpvlG
xgSm6tZpG6doEtZ7Htz8QKDvwRPcHXlAa2haQ9PgCS6EYLFkb3F6XvaQU+C7pRSYZk5p5phWTmnl
lHZOgcVZdl+SUzrQqfQVB1yx6R8P5bcZsILLbj/ypupcza3/BQAA//8DAFBLAwQUAAYACAAAACEA
nGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVs
c4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3cc
aloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOP
VuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2ed
NS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAA
AAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAM6M+vBgMAANIHAAAfAAAA
AAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgA
AAAhAOFRNx/PBgAA5hsAABoAAAAAAAAAAAAAAAAAYwUAAGNsaXBib2FyZC90aGVtZS90aGVtZTEu
eG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAagwAAGNsaXBib2Fy
ZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAABtDQAAAAA=
"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>PONV wording</p></td></tr></tbody></table></td></tr></tbody></table><p>Children aged over 1 month and adolescents:</p><p>&nbsp;</p><p>It is recommended that Zofran is given as an injection.</p><p>&nbsp;</p><p><strong>Patients with moderate or severe liver problems</strong></p><p>The total daily dose should not be more than 8 mg (two 5 ml spoonfuls).</p><p>Zofran syrup should start to work within one or two hours of taking a dose.</p><p><strong>&nbsp;</strong></p><p><strong>If you are sick (vomit) within one hour of taking a dose</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take the same dose again</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; otherwise, do not take more Zofran syrup than the label says.</p><p>If you continue to feel sick, tell your doctor or nurse.</p><p>&nbsp;</p><p><strong>a.&nbsp; </strong><strong>If you take more Zofran syrup than you should</strong></p><p>If you or your child take more Zofran than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p>&nbsp;</p><p><strong>b. </strong><strong>If you forget to take Zofran syrup</strong></p><p>If you miss a dose <strong>and</strong> feel sick or vomit:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take Zofran syrup as soon as possible, then</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take your next dose at the usual time (as shown on the label)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you miss a dose but do not feel sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take the next dose as shown on the label</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; do not take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Zofran syrup can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could be serious</strong></p><p>Stop taking Zofran and seek medical help immediately if you or your child experience any of the following:</p><p>&nbsp;</p><p><strong>Allergic reactions</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheezing and chest pain or chest tightness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your eyelids, face, lips, mouth or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash - red spots or lumps under your skin (hives) anywhere on your body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse.</p><p><strong>&nbsp;</strong></p><p><strong>Myocardial ischemia: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden chest pain or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other side effects include:</strong></p><p><strong>Very common (may affect more than 1 in 10 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p><strong>&nbsp;</strong></p><p><strong>Common (may affect up to 1 in 10 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of warmth or flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to liver function test results (if you take Zofran syrup with a medicine called cisplatin, otherwise this side effect is uncommon).</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon (may affect up to 1 in 100 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, which can make you feel faint or dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uneven heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual body movements or shaking.</p><p><strong>&nbsp;</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy or light headed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)</p><p><strong>&nbsp;</strong></p><p><strong>Very rare (may affect up to 1 in 10,000 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor vision or temporary loss of eyesight, which usually comes back within 20 minutes.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.&nbsp;</p><p>&nbsp;</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Zofran syrup after the expiry date which is stated on the bottle and carton after &lsquo;Exp&rsquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Zofran syrup below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not refrigerate. Keep the bottle upright.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zofran syrup contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient is ondansetron. Each 5&nbsp;ml spoonful of Zofran syrup contains ondansetron 4&nbsp;mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are citric acid (E330), sodium citrate (E331), sodium benzoate (E211), sorbitol (E420), strawberry flavour and water. This medicinal product also contains very small amounts of ethanol (please see Section 2 above).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zofran syrup is a sugar-free, strawberry flavoured liquid. It is packed in 60 ml amber glass bottles with a child resistant cap containing 50 ml of Zofran syrup.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by MHRA in 01/2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي شراب زوفران على دواء يسمى أوندانسيترون. ينتمي هذا الدواء لمجموعة من الأدوية تسمى &quot;مضادات القيء&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم شراب زوفران في:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الغثيان والقيء الناجمين عن تلقي العلاج الكيميائي (في البالغين والأطفال) أو العلاج الإشعاعي لمرض السرطان (البالغون فقط).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الغثيان والقيء بعد إجراء العمليات الجراحية (البالغون فقط).</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الممرض أو الصيدلي إذا كنت تود الحصول على أي شرح إضافي بشأن هذه الاستخدامات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp; </strong><strong>موانع </strong><strong>تناول</strong><strong> شراب زوفران:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أبومورفين (يستخدم لعلاج مرض باركنسون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (الحساسية المفرطة) تجاه أوندانسيترون أو أيٍّ من المكونات الأخرى الموجودة <strong>بشراب</strong> زوفران أ(المُدرَجة في قسم: 6).</p><p dir="RTL">إن لم تكن متأكدًا، فاستشر الطبيب، أو الصيدلي أو الممرض قبل تناول شراب زوفران.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب. </strong><strong>&nbsp;الاحتياطات عند تناول شراب زوفران</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">راجع طبيبك أو الممرض أو الصيدلي قبل تناوُل <strong>شراب</strong> زوفران في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من مشاكل في القلب (على سبيل المثال: فشل القلب الاحتقاني الذي يُسبب ضيق في التَّنفُّس وتورُّم في الكاحلين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من عدم انتظام ضربات القلب (اضطرابات النَّظْم القلبي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه الأدوية المشابهة لأوندانسيترون، مثل: جرانيسيترون أو بالونوسيترون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشاكل بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من انسداد في الأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشاكل في مستويات الأملاح في الدَّم، مثل: البوتاسيوم والصوديوم والماغنسيوم.</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ينطبق عليك أيٌّ مما سبق، فتحدَّث مع طبيبك أو الممرض أو الصيدلي قبل تناوُل أقراص زوفران.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج. </strong><strong>&nbsp;التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى إخبار طبيبك، الممرض أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أدوية أخرى. يتضمن ذلك الأدوية التي تقوم بشرائها بدون وصفة طبية وكذلك الأدوية العشبية. ذلك لأن عقار زوفران قد يؤثر على طريقة عمل بعض الأدوية. كذلك قد تؤثر بعض الأدوية الأخرى على طريقة عمل عقار زوفران.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك أو الممرض أو الصيدلي إذا كنت تتناول أيًّا من الأدوية الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كَرْبامازِيبين أو فينيتوين اللذين يُستَخدَمان لعلاج الصَّرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، وهو دواء يُستَخدَم لعلاج العدوى مثل السُّل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية مثل إريثروميسين أو كيتوكونازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لاضطرابات النظم القلبي، والتي تُستَخدَم لعلاج عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا التي تُستَخدَم لعلاج بعض مشاكل القلب أو العين أو القلق أو لمنع حدوث الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_225" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:-130.95pt;margin-top:3.2pt;width:45pt;height:45pt;text-indent:0;
 z-index:251657216;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_225'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">PONV wording arrow</p></td></tr></tbody></table></td></tr></tbody></table><p>ترامادول، وهو أحد مُسَكِّنات الألم.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على القلب (مثل: هالُوبِيرِيدُول أو ميثادون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية السرطان (لا سيَّما الأنثراسيكلينات وتراستوزوماب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إعادة امتصاص السيروتونين الانتقائية التي تُستَخدَم لعلاج الاكتئاب و/أو القلق، وتشمل: فلوكسيتين، باروكسيتين، سيرترالين، فلوفوكسامين، سيتالوبرام، إسيتالوبرام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إعادة امتصاص السيروتونين-النورإيبينفرين التي تُستَخدَم لعلاج الاكتئاب و/أو القلق، وتشمل فينلافاكسين، دولوكسيتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ينطبق عليك أيٌّ مما سبق، فتحدَّث مع طبيبك أو الممرض أو الصيدلي قبل تناوُل أقراص زوفران.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي على الفور إذا ظهرت عليك أي من هذه الأعراض أثناء وبعد العلاج بزوفران.</p><p dir="RTL">إذا كنت تعاني من ألم مفاجئ في الصدر أو ضيق في الصدر (إقفار عضلة القلب)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. الحمل والرضاعة </strong></p><p dir="RTL">لا تستخدمي العقار أثناء الثُّلث الأول من الحَمْل إلا بعد إجراء مناقشة مع طبيبكِ بخصوص الفوائد والمخاطر المُحتَمَلة لخيارات العلاج المختلفة عليكِ وعلى جنينكِ.&nbsp;ذلك لأن عقار زوفران قد يؤدي إلى حدوث زيادة طفيفة في خطر إصابة الطفل المولود بانشقاق الشفة و/أو الحنك المشقوق (فتحات أو شقوق في الشفة العليا و/أو سقف الفم). إذا كنتِ حاملًا بالفعل، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُل عقار زوفران. إذا كنتِ سيدة ولديكِ القدرة على الحَمْل، فقد تقدم لك الإستشارة باستخدام وسيلة فعَّالة لمنع الحَمْل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تمارسي الرضاعة الطبيعية إذا كنتِ تتناولين عقار زوفران. ذلك نظرًا لمرور كميات قليلة منه إلى حليب الأم. استشيري طبيبكِ أو قابلتكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. معلومات هامة حول بعض مكونات شراب زوفران </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على سوربيتول (إي 420) قيمة السعرات الحرارية 2.6 كيلوكالوري/ جرام سوربيتول. إن كان طبيبك قد أبلغك أنك مصاب بعدم تحمل بعض السكريات، فاستشر طبيبك قبل تناول هذا الدواء. قد يكون لسوربيتول تأثيرًا ملينًا بسيطًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج الدوائي على كميات صغيرة من الإيثانول (الكحول)، أقل من 0.004 مل في الملعقة التي تبلغ 5 مل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناوَل دائمًا شراب زوفران كما أخبرك طبيبك بالضبط. يجب مراجعة طبيبك أو الممرض أو الصيدلي إذا لم تكن متأكدًا من كيفية التناوُل. ستعتمد الجرعة الموصوفة لك على العلاج الذي تتلقاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تخلط شراب زوفران بأي شيء (ولا حتى الماء) قبل بلعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للوقاية من الغثيان والقيء الناجمين عن تلقي العلاج الكيميائي أو العلاج الإشعاعي </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">في يوم تلقي العلاج الكيميائي أو العلاج الإشعاعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المُعتادة للبالغين 8 مجم يتم تناوُلها قبل العلاج بساعة واحدة إلى ساعتين وأخرى قدرها 8 مجم بعد إثنا عشرة ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأيام التَّالية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المُعتادة للبالغين 8 مجم مرّتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُعطى هذه الجرعة لمدة تصل إلى 5 أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_223" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:-139.95pt;margin-top:3.2pt;width:45pt;height:45pt;z-index:251658240;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">CINV wording arrow</p></td></tr></tbody></table></td></tr></tbody></table><p>الأطفال ممن تزيد أعمارهم عن 6 أشهر والمراهقون:</p><p>&nbsp;</p><p dir="RTL">سيحدد الطبيب الجرعة وفقًا لحجم الطفل (مساحة سطح الجسم) أو وزنه. ألق نظرة على المُلصَق للاطلاع على المزيد من المعلومات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة للطفل تصل إلى ملعقة 5 مللي مرتان يوميًّا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; يمكن إعطاء هذه الجرعة لمدة تصل إلى 5 أيام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للوقاية من الغثيان والقيء بعد إجراء العمليات الجراحية</strong></p><p dir="RTL">الجرعة المعتادة للبالغين هي 4 ملاعق 5 مللي قبل العملية الجراحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_224" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:-130.95pt;
 margin-top:3.2pt;width:45pt;height:45pt;z-index:251659264;visibility:visible'
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">PONV wording arrow</p></td></tr></tbody></table></td></tr></tbody></table><p>الأطفال ممن تزيد أعمارهم عن شهرٍ واحدٍ والمراهقون:</p><p>&nbsp;</p><p dir="RTL">يُوصى بإعطاء عقار زوفران في هيئة حَقْن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى المُصابون بمشاكل متوسطة أو شديدة في الكبد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجب أن يتجاوز إجمالي الجرعة اليومية 8 ملجم (ملعقتان ملء 5 مللي).</p><p dir="RTL">يفترض بدء تأثير شراب زوفران بعد ساعة أو ساعتين من تناول الجرعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إن كنت مصابًا بالإعياء (القيء) خلال ساعة واحدة من تناول إحدى الجرعات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول نفس الجرعة مرة أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلاف ذلك، لا تتناول من شراب زوفران كمية أكبر من المذكورة على المُلصَق.</p><p dir="RTL">إذا استمر شعورك بالإعياء، فأخبِر طبيبك أو الممرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من شراب زوفران</strong></p><p dir="RTL">إذا تناولت أو تناول طفلك كمية أكثر مما يجب من شراب زوفران، فتحدَّث إلى الطبيب أو اذهب إلى المستشفى فورًا. خذ معك عبوة الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب. </strong><strong>نسيان تناول جرعة من شراب زوفران</strong></p><p dir="RTL">إذا نسيت تناوُل إحدى الجرعات وشعرت بإعياء أو رغبة في التقيؤ:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تناول شراب زوفران في أسرع وقت ممكن، ثم</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تناول جرعتك التالية في موعدها المعتاد (على النحو المُبيَّن على المُلصَق)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لا تتناول جرعة مضاعفة لتعويض جرعة قد تم نسيانها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت تناوُل إحدى الجرعات ولكن لم تشعر بإعياء</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تناوَل الجرعة التَّالية على النحو المُبيَّن على المُلصَق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة قد تم نسيانها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، قد يُسبب شراب زوفران أعراض جانبيةً، على الرغم من عدم حدوثها لدى الجميع.&nbsp;</p><p dir="RTL">قد تكون بعض الأعراض الجانبية خطيرة</p><p dir="RTL">&nbsp;توقف عن تناول زوفران واطلب المساعدة الطبية على الفور اذا واجهت او اذا واجه طفلك أيًا مما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة مفاجئة من أزيز الصدر وألم الصدر أو ضيق الصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الجفون أو الوجه أو الشفتين أو الفم أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفحًا جلديًّا -بقعًا حمراء أو كتلًا أسفل الجلد (شرى [أرتكاريا]) في أيِّ مكان على الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور الصحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نقص تروية عضلة القلب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم مفاجئ في الصدر أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ضيق في الصدر</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تتضمن باقي الآثار الجانبية ما يلي:</strong></p><p dir="RTL"><strong>بالغة الشيوع (قد تصيب أكثر من 1 من بين 10 أشخاص) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب حتى 1 من بين 10 أشخاص) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدفء أو احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغيُّرات في نتائج اختبارات وظائف الكبد (إذا تناولت أقراص زوفران مع دواء يُسمى سِيسْبلاتين، خلاف ذلك يكون هذا العرض الجانبي غير شائع).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>100 </strong><strong>شخص</strong><strong>) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فُواق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم، الأمر الذي قد يجعلك تشعر بالإغماء أو الدوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنُّجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير معتادة للجسم أو اهتزازه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>1000 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدّوخة أو الدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في النَّظْم القلبي (يُسبب في بعض الأحيان فقدانًا مفاجئًا للوعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>10000 </strong><strong>شخص</strong><strong>) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الرؤية أو فقدان الرؤية المؤقت، حيث تعود الرؤية عادةً في غضون 20 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أُصبت بأية أعراض جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض. يشمل ذلك أية أعراض جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بإبلاغك عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم عقار زوفران أقراص بعد تاريخ انتهاء الصلاحية المدون على العبوة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُخزن شراب زوفران في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يحفظ في الثلاجة. احتفظ بالزجاجة في وضعية قائمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;لا تتخلص من أي أدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أوندانسيترون. تحتوي كل ملعقة ملء 5 مللي على أوندانسيترون 4 ملجم.</p><p dir="RTL">تتضمن بقية المكونات حمض الستريك (إي 330)، وسترات الصوديوم (إي 331)، وبنزوات الصوديوم (إي 211)، وسوربيتول (إي 420)، ونكهة الفراولة والماء. يحتوي هذا المنتج الدوائي كذلك على كميات ضئيلة من الإيثانول (يرجى قراءة قسم 2 أعلاه).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شراب زوفران سائل خالٍ من السكر، بنكهة الفراولة. يعبأ في زجاجة من الزجاج الكهرماني ذات غطاء مقاوم للأطفال تحتوي على 50 مللي من شراب زوفران.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النَّشرة من قبل المملكة المتحدة في تاريخ  01/2022 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zofran® Syrup 4 mg/5 ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml contains 4 mg of ondansetron as the hydrochloride dihydrate.

Excipient(s) with known effect: 
Each 5 ml also contain 2.1 g of sorbitol (E420) and 3 mg of ethanol (see section 4.4).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution.
Sugar-free strawberry flavoured liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Adults:</u></em></p><p>Zofran Syrup is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.</p><p>Zofran Syrup is indicated for the prevention of post-operative nausea and vomiting (PONV).</p><p>For treatment of established PONV, administration by injection is recommended.</p><p>&nbsp;</p><p><em><u>Paediatric Population:</u></em></p><p>Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in</p><p>children aged &ge;6 months.</p><p>No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged &ge;1 month administration by IV injection is recommended for this purpose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology&nbsp;&nbsp;&nbsp;&nbsp; </u></p><p>&nbsp;</p><p><u>C</u><u>hemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV)</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge.</p><p>&nbsp;</p><p><em>Emetogenic chemotherapy and radiotherapy: </em>Zofran can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration.</p><p>&nbsp;</p><p>The recommended oral dose is 8 mg taken 1 to 2 hours before chemotherapy or radiation treatment, followed by 8 mg every 12 hours for a maximum of 5 days to protect against delayed or prolonged emesis.</p><p>&nbsp;</p><p><em>For highly emetogenic chemotherapy</em>: a single dose of up to 24 mg Zofran taken with 12 mg oral dexamethasone sodium phosphate, 1 to 2 hours before chemotherapy, may be used.</p><p>To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with</p><p>Zofran may be continued for up to 5 days after a course of treatment.</p><p>&nbsp;</p><p>The recommended dose for oral administration is 8 mg to be taken twice daily.</p><p>&nbsp;</p><p><em>Paediatric Population</em></p><p><em>&nbsp;</em></p><p><!--[if gte vml 1]><v:group id="Group_x0020_1"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:295.7pt;margin-top:11.5pt;width:3pt;height:.5pt;z-index:-251657216;
 mso-position-horizontal-relative:page' coordorigin="5914,230" coordsize="60,10"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Freeform_x0020_3" o:spid="_x0000_s1027" style='position:absolute;
  left:5914;top:230;width:60;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="60,10" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDjtHsiwgAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
FITvwv6H8Ba8aaqHRapRRNZFWEGte9jjo3k21ealNLHWf28EweMwM98ws0VnK9FS40vHCkbDBARx
7nTJhYK/43owAeEDssbKMSm4k4fF/KM3w1S7Gx+ozUIhIoR9igpMCHUqpc8NWfRDVxNH7+QaiyHK
ppC6wVuE20qOk+RLWiw5LhisaWUov2RXq0Cv/X6U8O/qe/n/M9m2u7PJz0el+p/dcgoiUBfe4Vd7
oxWM4Xkl3gA5fwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDjtHsiwgAAANoAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" path="m,5r60,e" filled="f" strokeweight=".58pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,235;60,235"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="6" height="2" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><em>C</em><em>I</em><em>N</em><em>V in children and adolescents aged 6 months to 17 years</em></p><p>The dose for CINV can be calculated based on body surface area (BSA) or weight &ndash; see below. In paediatric clinical studies, ondansetron was given by IV infusion diluted in 25 to 50 mL of saline or</p><p>other compatible infusion fluid and infused over not less than 15 minutes.</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see section</p><p>4.4).</p><p>&nbsp;</p><p>There are no data from controlled clinical trials on the use of Zofran in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of Zofran for radiotherapy-induced nausea and vomiting in children.</p><p>&nbsp;</p><p>Dosing by BSA</p><p>Zofran should be administered immediately before chemotherapy as a single intravenous dose of</p><p>5 mg/m2. The single intravenous dose must not exceed 8 mg.</p><p>&nbsp;</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 1). The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p><u>T</u><u>able 1: BSA-based dosing for CINV (aged 6 months to 17 years)</u></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>BSA</p></td><td style="vertical-align:top"><p>Day 1 (a,b)</p></td><td style="vertical-align:top"><p>Days 2-6(b)</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.6 m2</p></td><td style="vertical-align:top"><p>5 mg/m2 IV plus 2 mg syrup after</p><p>12 hours</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 0.6 m2 to &le; 1.2 m2</p></td><td style="vertical-align:top"><p>5 mg/m2 IV plus 4 mg syrup or</p><p>tablet after 12 hours</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every</p><p>12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.2 m2</p></td><td style="vertical-align:top"><p>5 mg/m2 or 8 mg IV plus</p><p>8 mg syrup or tablet after 12 hours</p></td><td style="vertical-align:top"><p>8 mg syrup or tablet every 12</p><p>hours</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous dose must not exceed 8 mg.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg</p><p>&nbsp;</p><p>Dosing by bodyweight</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (sections 4.4. and 5.1).</p><p>Zofran should be administered immediately before chemotherapy as a single intravenous dose of</p><p>0.15 mg/kg. The intravenous dose must not exceed 8 mg.</p><p>Two further intravenous doses may be given in 4-hourly intervals.</p><p>&nbsp;</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 2). The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p><u>T</u><u>able 2: Weight-based dosing for CINV (aged 6 months to 17 years)</u></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Body Weight</p></td><td style="vertical-align:top"><p>Day 1 (a,b)</p></td><td style="vertical-align:top"><p>Days 2-6(b)</p></td></tr><tr><td style="vertical-align:top"><p>&le; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV</p><p>every 4 hours</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV</p><p>every 4 hours</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every</p><p>12 hours</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous dose must not exceed 8 mg.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No alteration of oral dose or frequency of administration is required.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Post operative nausea and vomiting (PONV):</u></p><p>&nbsp;</p><p><em>Adults</em></p><p><em>For the prevention of PONV: </em>Zofran can be administered orally or by intravenous or intramuscular injection.</p><p>&nbsp;</p><p>The recommended oral dose is 16 mg one hour prior to anaesthesia.</p><p>&nbsp;</p><p>For the treatment of established PONV,<em> </em>intravenous or intramuscular administration is recommended.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p><em>PONV in children and adolescents (aged 1 month to 17 years)</em></p><p>&nbsp;</p><p><em>O</em><em>ral formulation:</em></p><p>No studies have been conducted on the use of orally administered ondansetron in the prevention or treatment of post-operative nausea and vomiting; slow IV injection (not less than 30 seconds) is</p><p>recommended for this purpose.</p><p>&nbsp;</p><p><em>I</em><em>njection:</em></p><p>For prevention of PONV in paediatric patients having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30</p><p>seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of</p><p>anaesthesia.</p><p>&nbsp;</p><p>For the treatment of PONV after surgery in paediatric patients having surgery performed under general anaesthesia, a single dose of Zofran may be administered by slow intravenous injection (not less than</p><p>30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg.</p><p>&nbsp;</p><p>There are no data on the use of Zofran in the treatment of PONV in children below 2 years of age.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>There is limited experience in the use of Zofran in the prevention and treatment of PONV in the elderly, however Zofran is well tolerated in patients over 65 years receiving chemotherapy.</p><p>&nbsp;</p><p><u>For both indications:</u></p><p>&nbsp;</p><p><em>Patients with Renal impairment</em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration are required.</p><p>&nbsp;</p><p><em>Patients with Hepatic impairment</em></p><p>Clearance of Zofran is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function.&nbsp; In such patients a total daily dose of 8 mg</p><p>should not be exceeded.</p><p>&nbsp;</p><p><em>Patients with poor Sparteine/Debrisoquine Metabolism</em></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure</p><p>levels no different from those of the general population.&nbsp; No alteration of daily dosage or frequency of dosing is required.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Concomitant use with apomorphine is contraindicated (see section 4.5 interactions). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT3 receptor antagonists.</p><p>&nbsp;</p><p>Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.</p><p>&nbsp;</p><p>Ondansetron prolongs the QT interval in a dose-dependent manner (see section 5.1).&nbsp; In addition, post- marketing cases of Torsade de Pointes have been reported in patients using ondansetron.&nbsp; Avoid ondansetron in patients with congenital long QT syndrome.&nbsp; Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.</p><p>&nbsp;</p><p>Myocardial ischemia has been reported in patients treated with ondansetron. In some cases, predominantly during intravenous administration, the symptoms appeared immediately after administration but recovered with prompt treatment. Therefore, caution should be exercised during and after administration of ondansetron.</p><p>Hypokalaemia and hypomagnesaemia should be corrected prior to ondansetron administration.</p><p>&nbsp;</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use</p><p>of ondansetron and other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs) (see section 4.5). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.</p><p>&nbsp;</p><p>As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.</p><p>&nbsp;</p><p>In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.</p><p>&nbsp;</p><p>Patients with rare hereditary problems of fructose intolerance should not take this medicine as it contains sorbitol. Sorbitol may have a mild laxative effect and has a calorific value of 2.6 kcal/g.</p><p>&nbsp;</p><p>This medicine contains small amounts of ethanol (alcohol), less than 100 mg per 5 ml.</p><p><em>Paediatric Population</em></p><p>Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.</p><p>&nbsp;</p><p><u>C</u><u>I</u><u>N</u><u>V</u><u>:</u> When calculating the dose on an mg/kg basis and administering three doses at 4-hour intervals, the total daily dose will be higher than if one single dose of 5 mg/m2 followed by an oral dose is given. The comparative efficacy of these two different dosing regimens has not been investigated in clinical trials. Cross-trial comparison indicates similar efficacy for both regimens (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly co-administered with it. Specific studies have shown that there are no interactions when ondansetron is administered with alcohol, temazepam, furosemide, alfentanil, tramadol, morphine, lidocaine, thiopental or propofol.</p><p>&nbsp;</p><p>Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2.&nbsp; Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.</p><p>&nbsp;</p><p>Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT</p><p>interval and/or cause electrolyte abnormalities. (See section 4.4)</p><p>&nbsp;</p><p>Use of ondansetron with QT prolonging drugs may result in additional QT prolongation. Concomitant use of ondansetron with cardiotoxic drugs (e.g. anthracyclines (such as doxorubicin, daunorubicin) or trastuzumab), antibiotics (such as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of arrhythmias. (See section 4.4).</p><p>&nbsp;</p><p><em>Serotonergic Drugs (e.g. SSRIs and SNRIs): </em>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs). (See section 4.4)</p><p>&nbsp;</p><p><em>Apomorphine: </em>Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.</p><p>&nbsp;</p><p><em>Phenytoin, Carbamazepine and Rifampicin: &nbsp;</em>In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.</p><p>&nbsp;</p><p><em>Tramadol: &nbsp;</em>Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential </u></p><p>Women of childbearing potential should consider the use of contraception.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>Based on human experience from epidemiological studies, ondansetron is suspected to cause orofacial malformations when administered during the first trimester of pregnancy.</p><p>In one cohort study including 1.8 million pregnancies, first trimester ondansetron use was associated with an increased risk of oral clefts (3 additional cases per 10 000 women treated; adjusted relative risk, 1.24, (95% CI 1.03-1.48)).</p><p>The available epidemiological studies on cardiac malformations show conflicting results.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Ondansetron should not be used during the first trimester of pregnancy.</p><p>&nbsp;</p><p><u>B</u><u>r</u><u>east-feeding</u></p><p>Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving Zofran should not breast-feed their babies.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There is no information on the effects of ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zofran has no or negligible influence on the ability to drive and use machines.</p><p>In psychomotor testing ondansetron does not impair performance nor cause sedation. No detrimental effects on such activities are predicted from the pharmacology of ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tabulated list of adverse reactions</u>&nbsp;</p><p>&nbsp;</p><p>Adverse events are listed below by system organ class and frequency.&nbsp; Frequencies are defined as:</p><p>very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to</p><p>&lt;1/1000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Rare, very rare and not known events were generally determined from post-marketing spontaneous data.</p><p>&nbsp;</p><p>The following frequencies are estimated at the standard recommended doses of ondansetron. The adverse event profiles in children and adolescents were comparable to that seen in adults.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia)<sup>(1)</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dizziness predominantly during rapid IV administration.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Transient visual disturbances (e.g. blurred vision) predominantly during IV administration.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Transient blindness predominantly during IV administration <sup>(2)</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Arrhythmias, chest pain with or without ST segment depression, bradycardia.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>QTc prolongation (including Torsade de Pointes).</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Myocardial ischemia*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Sensation of warmth or flushing.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypotension.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;Hiccups.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Asymptomatic increases in liver function tests <sup>(3)</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>1.&nbsp; &nbsp;Observed without definitive evidence of persistent clinical sequelae.</p><p>2.&nbsp; &nbsp;The majority of the blindness cases reported resolved within 20 minutes. Most patients</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.</p><p>3.&nbsp; &nbsp;These events were observed commonly in patients receiving chemotherapy with cisplatin.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp; These types of adverse drug reactions have been derived from post-marketing</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience with Zofran via spontaneous case reports and literature cases. Because these</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions are reported voluntarily from a population of uncertain size, it is not possible</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to reliably estimate their frequency which is therefore categorized as not known.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call centre: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa<em> </em></p><p>&nbsp;</p><p>Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and Signs</u></p><p>There is limited experience of ondansetron overdose. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second-degree AV block</p><p>&nbsp;</p><p>Ondansetron prolongs the QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Paediatric cases consistent with serotonin syndrome have been reported after inadvertent oral overdoses of ondansetron (exceeded estimated ingestion of 4 mg/kg) in infants and children aged 12 months to 2 years.</p><p>&nbsp;</p><p><u>Management</u></p><p>There is no specific antidote for ondansetron, therefore in all cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.</p><p>&nbsp;</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p><p>&nbsp;</p><p>The use of ipecacuanha to treat overdose with ondansetron is not recommended, as patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Serotonin (5HT3) antagonist, ATC code: A04AA01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors.&nbsp; Ondansetron blocks the initiation of this reflex.&nbsp; Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism.&nbsp; Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system.</p><p>&nbsp;</p><p>The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.</p><p>&nbsp;</p><p>Ondansetron does not alter plasma prolactin concentrations.</p><p>&nbsp;</p><p><u>Clinical safety and efficacy</u></p><p>The role of ondansetron in opiate-induced emesis is not yet established.</p><p><u>&nbsp;</u></p><p><u>Q</u><u>T Prolongation</u></p><p>The effect of ondansetron on the QTc interval was evaluated in a double blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes.&nbsp; At the highest tested dose of 32 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 19.6 (21.5) msec. At the lower tested dose of 8 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 5.8 (7.8) msec. In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p><u>C</u><u>I</u><u>N</u><u>V</u></p><p>The efficacy of ondansetron in the control of emesis and nausea induced by cancer chemotherapy was assessed in a double-blind randomised trial in 415 patients aged 1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either ondansetron 5 mg/m2 intravenous and ondansetron</p><p>4 mg orally after 8 to 12 hours or ondansetron 0.45 mg/kg intravenous and placebo orally after 8 to</p><p>12 hrs. Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. Complete control of emesis on worst day of chemotherapy was 49% (5 mg/m2 intravenous and ondansetron 4 mg orally) and 41% (0.45 mg/kg intravenous and placebo orally). Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>&nbsp;</p><p>A double-blind randomised placebo-controlled trial (S3AB4003) in 438 patients aged 1 to 17 years demonstrated complete control of emesis on worst day of chemotherapy in:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73% of patients when ondansetron was administered intravenously at a dose of 5 mg/m2</p><p>intravenous together with 2 to 4 mg dexamethasone orally</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 71% of patients when ondansetron was administered as syrup at a dose of 8 mg together with 2 to 4 mg dexamethasone orally on the days of chemotherapy.</p><p>&nbsp;</p><p>Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>&nbsp;</p><p>The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in an open-label, non-comparative, single-arm study (S3A40320). All children received three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before the start of chemotherapy and then at 4 and 8 hours after the first dose. Complete control of emesis was achieved in 56% of patients.</p><p>&nbsp;</p><p>Another open-label, non-comparative, single-arm study (S3A239) investigated the efficacy of one intravenous dose of 0.15 mg/kg ondansetron followed by two oral ondansetron doses of 4 mg for children aged &lt; 12 years and 8 mg for children aged &ge; 12 years (total no. of children n= 28). Complete control of emesis was achieved in 42% of patients.</p><p>&nbsp;</p><p><u>PONV</u></p><p>The efficacy of a single dose of ondansetron in the prevention of post-operative nausea and vomiting was investigated in a randomised, double-blind, placebo-controlled study in 670 children aged 1 to 24 months (post-conceptual age &ge;44 weeks, weight &ge; 3 kg).&nbsp; Included subjects were scheduled to undergo elective surgery under general anaesthesia and had an ASA status &le; III.&nbsp; A single dose of ondansetron</p><p>0.1 mg/kg was administered within five minutes following induction of anaesthesia. The proportion of subjects who experienced at least one emetic episode during the 24-hour assessment period (ITT) was greater for patients on placebo than those receiving ondansetron ((28% vs. 11%, p &lt;0.0001).</p><p>&nbsp;</p><p>Four double-blind, placebo-controlled studies have been performed in 1469 male and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients were randomised to either single intravenous doses of ondansetron (0.1 mg/kg for paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing more than 40 kg; number of patients = 735)) or placebo (number of patients = 734). Study drug was administered over at least 30 seconds, immediately prior to or following anaesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarised in Table 3.</p><p>&nbsp;</p><p><u>T</u><u>able 3:&nbsp; Prevention and treatment of PONV in Paediatric Patients &ndash; Treatment response over 24 hours</u></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Ondansetron %</p></td><td style="vertical-align:top"><p>Placebo %</p></td><td style="vertical-align:top"><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>S3A380</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT09</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3A381</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no nausea</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no emesis</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about 30 ng/mL are attained approximately 1.5 hours after an 8 mg dose. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Mean bioavailability in healthy male subjects, following the oral administration of a single 8 mg tablet, is approximately 55 to 60%.&nbsp; Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids. The disposition of ondansetron following oral, intramuscular (IM) and intravenous (IV) dosing is similar with a terminal half life of about 3 hours and steady state volume of distribution of about 140 L.&nbsp; Equivalent systemic exposure is achieved after IM and IV administration of ondansetron.</p><p>&nbsp;</p><p>A 4 mg intravenous infusion of ondansetron given over 5 minutes results in peak plasma concentrations of about 65 ng/mL.&nbsp; Following intramuscular administration of ondansetron, peak plasma concentrations of about 25 ng/mL are attained within 10 minutes of injection.</p><p>&nbsp;</p><p>Following administration of ondansetron suppository, plasma ondansetron concentrations become detectable between 15 and 60 minutes after dosing. Concentrations rise in an essentially linear fashion, until peak concentrations of 20-30 ng/mL are attained, typically 6 hours after dosing. Plasma concentrations then fall, but at a slower rate than observed following oral dosing due to continued absorption of ondansetron. The absolute bioavailability of ondansetron from the suppository is approximately 60% and is not affected by gender. The half life of the elimination phase following suppository administration is determined by the rate of ondansetron absorption, not systemic clearance and is approximately 6 hours.&nbsp; Females show a small, clinically insignificant, increase in half-life in comparison with males.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Ondansetron is not highly protein bound (70-76%).</p><p>&nbsp;</p><p><u>Biotransformation and Elimination</u></p><p>Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. Less than 5% of the absorbed dose is excreted unchanged in the urine. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron&#39;s pharmacokinetics. The pharmacokinetic properties of ondansetron are unchanged on repeat dosing.</p><p>&nbsp;</p><p><u>Special Patient Populations</u></p><p>&nbsp;</p><p><em>G</em><em>ender</em></p><p>Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of</p><p>distribution (adjusted for weight).</p><p>&nbsp;</p><p><em>C</em><em>hildren and Adolescents (aged 1 month to 17 years)</em></p><p>In paediatric patients aged 1 to 4 months (n=19) undergoing surgery, weight normalised clearance was approximately 30% slower than in patients aged 5 to 24 months (n=22) but comparable to the patients</p><p>aged 3 to 12 years. &nbsp;The half-life in the patient population aged 1 to 4 month was reported to average</p><p>6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. &nbsp;The differences in pharmacokinetic parameters in the 1 to 4 month patient population can be explained in part by the higher percentage of total body water in neonates and infants and a higher volume of distribution for water soluble drugs like ondansetron.</p><p>&nbsp;</p><p>In paediatric patients aged 3 to 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron were reduced in comparison to values with adult patients. Both parameters increased in a linear fashion with weight and by 12 years of age, the values were approaching those of young adults. When clearance and volume of distribution values were normalised by body weight, the values for these parameters were</p><p>similar between the different age group populations. Use of weight-based dosing compensates for age- related changes and is effective in normalising systemic exposure in paediatric patients.</p><p>&nbsp;</p><p>Population pharmacokinetic analysis was performed on 428 subjects (cancer patients, surgery patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of ondansetron.&nbsp; Based on this analysis, systemic exposure (AUC) of ondansetron following oral or IV dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 to 4 months. Volume was related to age and was lower in adults than in infants and children.&nbsp; Clearance was related to weight but not to age with the exception of infants aged 1 to 4 months.&nbsp; It is difficult to</p><p>conclude whether there was an additional reduction in clearance related to age in infants 1 to 4 months or simply inherent variability due to the low number of subjects studied in this age group. Since patients less than 6 months of age will only receive a single dose in PONV a decreased clearance is not likely to be clinically relevant.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (&lt; 65 years of age) and elderly subjects (&ge; 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials to support a different dosing recommendation for the elderly.</p><p>&nbsp;</p><p>Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients &ge;75 years of age compared to young adults. Specific dosing information is provided for patients over 65 years of age and over 75 years of age for intravenous dosing.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In patients with renal impairment (creatinine clearance 15-60 mL/min), both systemic clearance and volume of distribution are reduced following IV administration of ondansetron, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4 hours). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed ondansetron&#39;s pharmacokinetics to be essentially unchanged following IV administration.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>Following oral, intravenous or intramuscular dosing in patients with severe hepatic impairment, ondansetron&#39;s systemic clearance is markedly reduced with prolonged elimination half-lives (15-32</p><p>hours) and an oral bioavailability approaching 100% due to reduced pre-systemic metabolism.&nbsp; The</p><p>pharmacokinetics of ondansetron following administration as a suppository have not been evaluated in patients with hepatic impairment. The pharmacokinetics of ondansetron following administration as a suppository have not been evaluated in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Embryo-fetal development studies in rats and rabbits did not show evidence of harm to the fetus when ondansetron was administered during the period of organogenesis at approximately 6 and 24 times respectively the maximum recommended human oral dose of 24 mg/day, based on body surface area. In a pre- and postnatal developmental toxicity study, there were no effects upon pregnant rats and the pre- and postnatal development of their offspring, including reproductive performance at approximately 6 times the maximum recommended human oral dose of 24 mg/day based on body surface area.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid</p><p>Sodium citrate dihydrate</p><p>Sodium benzoate</p><p>Sorbitol solution</p><p>Strawberry flavour (contains ethanol*) Purified water</p><p>*This product contains 3 mg of ethanol per 5 mL of syrup.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store upright below 30&deg;C. Do not refrigerate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>60 ml amber glass bottle with a child resistant cap containing 50 ml of Zofran Syrup.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. For oral administration.&nbsp; For detailed information see the patient information leaflet included in every pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by MHRA in 01/2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>